Surgeons Convene at Vienna Symposium to Experience Baxter's HEMOPATCH Sealing Hemostat

18.08.25 06:30 Uhr

Werte in diesem Artikel

DEERFIELD, Ill., Aug. 18, 2025 /PRNewswire/ --

General Surgeon, Professor Selman Uranüs

Trusted for Over a Decade.
For over a decade, Hemopatch sealing hemostat has been a trusted companion in surgeries worldwide, providing critical support and precision under pressure, while evolving with the healthcare landscape.

A New Milestone: HEMOPATCH Sealing Hemostat, Now in Room Temperature
At a symposium in Vienna, Austria, Baxter unveiled the new Hemopatch sealing hemostat, a room-temperature collagen pad designed for hemostasis and sealing in both open and minimally invasive surgical procedures (MIS).1 This event marked the culmination of a decade-long collaboration between experts and developers. Hemopatch sealing hemostat is a more thoughtful solution shaped directly by feedback from those who use it daily. During the event, expert speakers shared how their insights and experiences drove the development of the new Hemopatch sealing hemostat, addressing an audience of surgeons from diverse specialties.

General Surgeon Professor Selman Uranüs, an early adopter who attended the symposium, said:
"I first used Hemopatch sealing hemostat for experimental testing. Since then, I've used it daily for its unique sealing properties, especially in laparoscopic surgery. Eliminating the need for refrigeration and extending shelf life are crucial improvements, ensuring it's available in the OR when it matters most."

A Reaffirmation of Trust and Partnership
The symposium reaffirmed our shared commitment to continuous innovation. The new Hemopatch sealing hemostat is designed for direct accessibility in the OR, reflecting our dedication to advancing surgical care with practical tools. Its new configuration is the result of close collaboration with surgeons, ensuring it meets real clinical needs.

We look forward to sharing more as the global roll out continues.

For more information on Hemopatch sealing hemostat,
Visit: https://advancedsurgery.baxter.eu/hemopatch

Reference

1.     Hemopatch sealing hemostat Instructions for Use.

Manufacturer:

Baxter Healthcare SA 

Thurgauerstrasse 130 Glattbrugg,

ZÜRICH, 8152 Switzerland 

Class of Device: III 

CE0123

This content is intended solely for healthcare professionals and should not be interpreted as medical advice. Please consult with a qualified healthcare provider for any health concerns. 

Hemopatch sealing hemostat is approved for use only in selected countries. For specific information on the availability and regulatory status of Hemopatch sealing hemostat room temperature in your country, we recommend contacting your local Baxter Healthcare sales representative. 

Baxter and Hemopatch are trademarks of Baxter International Inc. or its subsidiaries.

GBU-AS21-250025 (v1.0) 08/2025

HEMOPATCH Sealing Hemostat Indications and Important Risk Information

 

Baxter International Inc.

Photo - https://mma.prnewswire.com/media/2747929/Baxter_International_At_Vienna_Symposium.jpg
Photo - https://mma.prnewswire.com/media/2747930/Baxter_International_Hemopatch.jpg
Logo - https://mma.prnewswire.com/media/2687591/Baxter_International_Inc_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/surgeons-convene-at-vienna-symposium-to-experience-baxters-hemopatch-sealing-hemostat-302529527.html

In eigener Sache

Übrigens: Baxter International und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Baxter International

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Baxter International

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Baxter International Inc.

Wer­bung

Analysen zu Baxter International Inc.

DatumRatingAnalyst
16.10.2018Baxter International UnderweightBarclays Capital
28.07.2017Baxter International NeutralUBS AG
27.07.2017Baxter International OverweightBarclays Capital
14.07.2017Baxter International OutperformBMO Capital Markets
30.06.2017Baxter International OverweightCantor Fitzgerald
DatumRatingAnalyst
27.07.2017Baxter International OverweightBarclays Capital
14.07.2017Baxter International OutperformBMO Capital Markets
30.06.2017Baxter International OverweightCantor Fitzgerald
11.08.2015Baxter International OverweightBarclays Capital
10.07.2015Baxter International Market PerformBMO Capital Markets
DatumRatingAnalyst
28.07.2017Baxter International NeutralUBS AG
27.04.2017Baxter International Sector PerformRBC Capital Markets
26.10.2016Baxter International Sector PerformRBC Capital Markets
27.04.2016Baxter International Sector PerformRBC Capital Markets
13.07.2015Baxter International Sector PerformRBC Capital Markets
DatumRatingAnalyst
16.10.2018Baxter International UnderweightBarclays Capital
05.10.2011Baxter International sellCitigroup Corp.
06.10.2005Update Baxter International Inc.: ReduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Baxter International Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen